BMS, Kereos collaborate on imaging agents
Bristol-Myers Squibb Medical Imaging and Kereos have agreed to partner in the development and commercialization of novel molecular imaging agents. The goal is to develop agents that will detect disease on a molecular level, potentially enabling earlier
Bristol-Myers Squibb Medical Imaging and Kereos have agreed to partner in the development and commercialization of novel molecular imaging agents. The goal is to develop agents that will detect disease on a molecular level, potentially enabling earlier and more effective diagnosis and highly targeted treatment of cardiovascular diseases and cancer. The companies will work together to develop molecular imaging agents using Kereos' core technology. BMS Medical Imaging has obtained exclusive worldwide rights to develop and commercialize select cardiovascular molecular imaging agents for MR. Kereos has obtained exclusive worldwide rights to use a family of BMS targeting molecules with Kereos' core technology to develop and commercialize imaging agents and targeted therapeutics. These include KI-001, Kereos' lead candidate for early MR detection of tumors. In addition to working with BMS, Kereos is collaborating with Philips Medical Systems for the development of molecular imaging systems.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
